Plasma proteome analysis: 2D gels and chips

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 7, 2006, Pages 81-93

  Herosimczyk, A ^a,b   Dejeans, N ^b   Sayd, T ^c   Ozgo, M ^a   Skrzypczak, W F ^a   Mazur, Andrzej ^b,d  

^a WEST POMERANIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^b INRA and University of Auvergne   (France)

^c CEMAGREF   (France)

^d CRNH AUVERGNE   (France)

Author keywords

Plasma; Protein chips; Proteome; Proteomics; Two dimensional electrophoresis

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; DNA TOPOISOMERASE (ATP HYDROLYSING); HAPTOGLOBIN; IMMUNOGLOBULIN G; POLYACRYLAMIDE GEL; PREALBUMIN; PROTEOME;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CLINICAL RESEARCH; COMPUTER PROGRAM; CONFERENCE PAPER; ELECTROSPRAY; HEPATITIS B; HUMAN; IMAGE ANALYSIS; ISOELECTRIC POINT; LIVER CELL CARCINOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS;

BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; PLASMA; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 34047249035     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Honore B, Ostergaard M, Vorum H. Functional genomics studied by proteomics. Bioessays 2004; 26: 815-822.
2. Kennedy S. Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 2001; 120: 379-384.
3. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947-955.
4. Merrel K, Southwick K, Graves SW, Esplin MS, Levis NE, Thulin CD. Analysis of low-abundance low molecular-weight-serum proteins using mass spectrometry. J Biomol Tech 2004; 15: 238-248.
5. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096-1103.
6. Putnam FW. Ed. The plasma proteins. Academic Press New York , 1975; p. 481.
7. He QY, Lau GKK, Zhou Y, et al. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 2003; 3: 666-674.
8. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx 2004; 1: 226-234.
9. Petricoin III EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-1578.
10. Petricoin EF III, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
11. Rui Z, Jian-Guo J, Yuan-Peng T, Bing-Gen R. Use of serological methods to find biomarkers associated with breast cancer. Proteomics 2003; 3: 433-439.
12. Seow TK, Liang RC, Leow CK, Chung MC. Hepatocellular carcinoma : from beside to proteomics. Proteomics 2001; 1: 1249-1263.
13. Steel LF, Shumpert D, Trotter M, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003; 3: 601-609.
14. Somiari RI, Somiari S, Russel S, Shriver CD. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 215-225.
15. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-α subnit as potential serum biomarker in ovarian cancer: identification and characterisation using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-2911.
16. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
17. Bjorhall K, Miliotis T, Davidsson P. Comparision of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2004; 5: 307-317.
18. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitive analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17: 994-999.
19. Lauber WM, Caroll JA, Dufield DR, Kiesel JR, Radabaugh MR, Malone JP. Mass spectrometry compatibility of two-dimensional gel protein stains. Electrophoresis 2001; 22: 906-918.
20. Yates JR III. Mass spectrometry and the age of the proteome. J Mass Spectrom 1998; 33: 1-19.
21. Zhu H, Bilgin M, Snyder M. Proteomics. Annu Rev Biochem 2003; 72: 783-812.
22. Link AJ. 2-D Proteome Analysis Protocols. Methods Mol Biol 1999; 112.
23. Rabilloud T. Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis 1998; 19: 758-760.
24. Molloy MP. Two dimensional ectrophoresis of membrane proteins using immobilized pH gradients. Anal Biochem 2000; 280: 1-10.
25. Herbert BR, Molloy MP, Gooley AA, Walsh BJ, Bryson WG, Williams KL. Improved protein solubility in two-dimensional electrophoresis using tributyl phosphine as reducing agent. Electrophoresis 1998; 19: 845-851.
26. Berkelman T, Brubacher MG, Chang H. Important factors influencing protein solubility for 2-D electrophoresis. Bio-Rad Laboratories 2004; Inc., Hercules, CA 94547
27. Govorughina NI, Keizer-Gunnik A, van der Zee AG, de Jong S, de Bruijn HW, Bischoff R. Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and gamma-globulin depletion. J Chromatogr A 2003; 1009: 171-178.
28. Lollo BA, Harvey S, Liao J, et al. Improved two-dimensional gel electrophoresis representation of serum proteins by using ProtoClear™. Electrophoresis 1999; 20: 249-259.
29. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003; 3: 243-248.
30. Georgiou HM, Rice GE, Baker MS. Proteomic analysis of human plasma: failure of centrifugal ultrafiltration to remove albumin and other high molecular weight proteins. Proteomics 2001; 1: 1503-1506.
31. Schuchard MD, Melm CD, Crawford AS, et al. Immunoaffinity depletion of 20 high abundance human plasma proteins. Sigma-aldrich.com
32. Gromov PS, Ostergaard M, Gromova I, Celis JE. Human proteomic databases: a powerful resource for functional genomics in health and diesease. Prog Biophys Mol Biol 2002; 80: 3-22.
33. Sellers TA, Yates JR. Review of proteomics with applications to genetic epidemiology. Genet Epidemiol 2003; 24: 83-98.
34. Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000; 192: 280-288.
35. Görg A. Advances in 2D gel techniques. Proteomics: A Trends Guide. Elsevier Science 2000; 3-6.
36. Marengo E, Robotti E, Antonucci F, Cecconi D, Campostrini N, Righetti G. Numerical approaches for quantitative analysis of two-dimensional maps: a review of commercial software and home-made systems. Proteomics 2005; 5: 654-666.
37. He QY, Chiu JF. Proteomics in biomarker discovery and drug development. J Cell Biochem 2003; 89: 868-886.
38. Patterson SD. Proteomics: beginning to realize its promise. Arthritis Rheum 2004; 50: 3741-3744.
39. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 2001; 70: 437-473.
40. Sydor JR, Nock S. Protein expression profiling arrays: tools for the multiplexed highthroughput analysis of proteins. Proteome Sci 2003; 1: 3.
41. Wilson DS, Nock S. Recent developments in protein microarray technology. Angew Chem Int Ed Eng 2003; 42: 494-500.
42. Glokler J, Angenendt P. Protein and antibody microarray technology. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 797: 229-240.
43. Schweitzer B, Predki P, Snyder M. Microarrays to characterize protein interactions on a wholeproteome scale. Proteomics 2003; 3: 2190-2199.
44. Baary R, Solovier M. Quantitative protein profiling using antibody arrays. Proteomics 2004; 4: 3717-3126.
45. Templin MF, Stoll D, Schrenk M, Traub PC, Vohringer CF, Joos TO. Protein microarray technology. Drug Discov Today 2002; 7: 815-822.
46. Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003; 4: 963-971.
47. Missailidis S, Thomaidou D, Borbas KE, Price MR. Selection of aptamers with high affinity and high specifity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting. J Immunol Methods 2005; 296: 45-62.
48. Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PloS Biol 2005; 3: e123.
49. Delahunty C, Yates III JR. Protein identification using 2D-LC-MS/MS. Methods 2005; 35: 248-255.
50. Walgren JL, Thompson DC. Application of proteomic technologies in the drug development process. Toxicol Lett 2004; 149: 377-385.
51. Fella K, Gluckmann M, Hellman J, Karas M, Kramer PJ, Kroger M. Use of two-dimensional gel electrophoresis in predictive toxicology: Identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics 2005; 5: 1914-1927.
52. Omenn GS. Ed.: Exploring the human plasma proteome. The HUPO plasma proteome project (PPP). Proteomics 2005; 5: 3223-3550.